ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder ce… Read more
ReproCELL Incorporated - Asset Resilience Ratio
ReproCELL Incorporated (6RC) has an Asset Resilience Ratio of 33.28% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how ReproCELL Incorporated's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down ReproCELL Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.12 Billion | 33.28% |
| Total Liquid Assets | €3.12 Billion | 33.28% |
Asset Resilience Insights
- Very High Liquidity: ReproCELL Incorporated maintains exceptional liquid asset reserves at 33.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ReproCELL Incorporated Industry Peers by Asset Resilience Ratio
Compare ReproCELL Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for ReproCELL Incorporated (2015–2025)
The table below shows the annual Asset Resilience Ratio data for ReproCELL Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 11.56% | €1.12 Billion | €9.67 Billion | -28.51pp |
| 2024-03-31 | 40.07% | €3.63 Billion | €9.05 Billion | -13.36pp |
| 2023-03-31 | 53.43% | €4.46 Billion | €8.36 Billion | +28.73pp |
| 2022-03-31 | 24.71% | €2.00 Billion | €8.10 Billion | -8.37pp |
| 2021-03-31 | 33.07% | €2.00 Billion | €6.05 Billion | +23.92pp |
| 2020-03-31 | 9.16% | €600.00 Million | €6.55 Billion | -12.21pp |
| 2019-03-31 | 21.36% | €1.60 Billion | €7.49 Billion | -8.95pp |
| 2018-03-31 | 30.31% | €2.00 Billion | €6.60 Billion | +4.85pp |
| 2017-03-31 | 25.46% | €2.00 Billion | €7.85 Billion | +0.37pp |
| 2016-03-31 | 25.09% | €2.00 Billion | €7.97 Billion | -1.24pp |
| 2015-03-31 | 26.32% | €2.00 Billion | €7.59 Billion | -- |